Eli Lilly is launching a campaign aimed at informing consumers about the seriousness of diabetes as a disease and the appropriate use of its weight-loss-related drugs.
Pharmaceutical giant Eli Lilly and Company is trying to clear up misconceptions about obesity care as it increases investment in its highly popular weight-loss drugs. With the latest phase of Lilly's "Get Better" campaign, the company aims to focus the importance of obesity treatment as a disease, and the appropriate use of anti-obesity medications.
" Countless medical professionals have repeatedly stressed that these drugs, including Novo's semaglutide, which is sold under the brand names Wegovy and Ozempic, are good medications for people who need them and shouldn't be used as a way to shed just a few pounds. Wegovy was approved by the FDA for chronic weight management in 2021, while Ozempic was approved about seven years ago for those with Type 2 diabetes with weight loss as a side effect.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly says Alzheimer’s drug approval delayed as FDA seeks input from advisersDrugmaker Eli Lilly says that approval of its experimental Alzheimer’s medication donanemab will be delayed beyond the end of March as the FDA plans to call a last-minute meeting of its advisers
Read more »
Eli Lilly's Alzheimer's drug delayed by FDA: ‘It was unexpected’On Friday, the FDA announced it would postpone a decision on Eli Lilly's potential Alzheimer's treatment donanemab.
Read more »
Eli Lilly's new ad says weight-loss drugs shouldn't be used out of 'vanity'In a new ad that nods to the 2024 Oscars, the pharmaceutical firm discourages people from using drugs like Mounjaro for cosmetic weight loss.
Read more »
Novo Nordisk and Eli Lilly rival soars 35% after promising weight loss drug resultsZealand Pharma's Phase 2 trial was an 'uniquivocal win' for a drug that can treat both liver disease and obesity, analysts said.
Read more »
Stocks making the biggest moves midday: Nvidia, Marvell Technology, Costco, Eli Lilly and moreThese are the stocks posting the largest moves in midday trading.
Read more »
Eli Lilly hits another Alzheimer's drug hurdle. But the main reason to own the stock remains solidly intactThe FDA decision delay is surprising and disappointing, Jim Cramer said Friday. But it's not a thesis-shattering event.
Read more »